Scholars@Duke
Journal cover image

Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.

Publication ,  Journal Article
Moorthy, GS; Greenberg, RG; Hornik, CD; Cassino, C; Ghahramani, P; Kumar, KR; Fowler, VG; Cohen-Wolkowiez, M
Published in: Clin Infect Dis
August 25, 2022
Published version (DOI) Open Access Copy (Duke) Link to item

Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics. Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.

Duke Scholars

Ganga Moorthy
Author Ganga Moorthy Pediatrics, Infectious Diseases
Rachel Gottron Greenberg
Author Rachel Gottron Greenberg Pediatrics, Neonatology
Chi Hornik
Author Chi Hornik Pediatrics, Critical Care Medicine
Karan Ravindra Kumar
Author Karan Ravindra Kumar Pediatrics, Critical Care Medicine
Vance Garrison Fowler Jr.
Author Vance Garrison Fowler Jr. Medicine, Infectious Diseases
Michael Cohen-Wolkowiez
Author Michael Cohen-Wolkowiez Pediatrics, Infectious Diseases
Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

10.1093/cid/ciab1015

EISSN

1537-6591

Publication Date

August 25, 2022

Volume

75

Issue

2

Start / End Page

338 / 341

Location

United States

Related Subject Headings

  • Staphylococcus aureus
  • Staphylococcal Infections
  • Microbiology
  • Methicillin-Resistant Staphylococcus aureus
  • Infant
  • Humans
  • Endopeptidases
  • Child
  • Anti-Bacterial Agents
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moorthy, G. S., Greenberg, R. G., Hornik, C. D., Cassino, C., Ghahramani, P., Kumar, K. R., … Cohen-Wolkowiez, M. (2022). Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection. Clin Infect Dis, 75(2), 338–341. https://doi.org/10.1093/cid/ciab1015
Moorthy, Ganga S., Rachel G. Greenberg, Chi D. Hornik, Cara Cassino, Parviz Ghahramani, Karan R. Kumar, Vance G. Fowler, and Michael Cohen-Wolkowiez. “Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.” Clin Infect Dis 75, no. 2 (August 25, 2022): 338–41. https://doi.org/10.1093/cid/ciab1015.
Moorthy GS, Greenberg RG, Hornik CD, Cassino C, Ghahramani P, Kumar KR, et al. Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection. Clin Infect Dis. 2022 Aug 25;75(2):338–41.
Moorthy, Ganga S., et al. “Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.” Clin Infect Dis, vol. 75, no. 2, Aug. 2022, pp. 338–41. Pubmed, doi:10.1093/cid/ciab1015.
Moorthy GS, Greenberg RG, Hornik CD, Cassino C, Ghahramani P, Kumar KR, Fowler VG, Cohen-Wolkowiez M. Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection. Clin Infect Dis. 2022 Aug 25;75(2):338–341.
Journal cover image

Published In

Clin Infect Dis

DOI

10.1093/cid/ciab1015

EISSN

1537-6591

Publication Date

August 25, 2022

Volume

75

Issue

2

Start / End Page

338 / 341

Location

United States

Related Subject Headings

  • Staphylococcus aureus
  • Staphylococcal Infections
  • Microbiology
  • Methicillin-Resistant Staphylococcus aureus
  • Infant
  • Humans
  • Endopeptidases
  • Child
  • Anti-Bacterial Agents
  • 3202 Clinical sciences